Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 20, 2017

View Archived Issues

Ionis Pharmaceuticals licenses second oral antisense drug to Janssen Biotech

Seattle Children's begins phase I study of CAR T-cell immunotherapy for CD19- and CD22-positive ALL

Bristol-Myers Squibb commences phase I/II trial of BMS-986251 for psoriasis

Aurigene and Orion identify lead compounds inhibiting protein arginine N-methyltransferase 5

First-in-human trial of affinity-enhanced TCR-gene transduced T-cell transfer targeting NY-ESO-1

Phase I results for AAV1 vectored immunoprophylaxis for HIV

FDA extends review period for Tlando NDA

Arginase-1/2 inhibitor OATD-02 a clinical candidate for cancer immunotherapy

FDA agrees on initial pediatric study plan for oral rimegepant

Phase III HAVEN 3 study of emicizumab in hemophilia A meets endpoints

NXT-596 demonstrates gamma-secretase inhibition as a therapeutic strategy against hearing loss

European Commission approves trastuzumab biosimilar Ontruzant

Novel molecule from Quadriga BioSciences shows promise for resistant glioblastoma

Phase III IMpower150 study of Tecentriq and Avastin in NSCLC meets PFS coprimary endpoint

Genoscience Pharma presents compounds for treating cancer

Rudong SIMR Biotech identifies novel GABRA5 inverse agonists

University of California, Oakland divulges erbB inhibitors

Sumitomo Dainippon Pharma discloses TLR7 antagonists

Galapagos reports topline results from phase II study of GLPG-2222 in cystic fibrosis

University of Texas System identifies novel sigma1/2 receptor modulators

European Commission approves Tasigna for pediatric Ph+ CML-CP

resTORbio advances phase IIb study of RTB-101 following recommendation of DMC

Umecrine initiates phase IIa study of GR-3027 in idiopathic hypersomnia

Celldex Therapeutics begins phase II study of CDX-3379 plus cetuximab

GlaxoSmithKline initiates first-in-human study of GSK-3511294 in mild to moderate asthma

Glenmark studies GBR-1342 for previously treated multiple myeloma in phase I study